Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.48 |
| ▸ | PRKCZ | Q05513 | 7/20 | 0.48 |
| ▸ | CDK4 | P11802 | 7/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.45 |
| ▸ | CCND1 | P24385 | 7/20 | 0.45 |
| ▸ | CCND3 | P30281 | 7/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.44 |
| ▸ | ITK | Q08881 | 2/20 | 0.44 |
| ▸ | JAK2 | O60674 | 2/20 | 0.44 |
| ▸ | TYK2 | P29597 | 2/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | CLK2 | P49760 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17251722 | 0.89 | CDK2 (0.53) | CDK2PRKCZCDK4CCNA2CCND1 | |
| SCHEMBL18562045 | 0.85 | CDK2 (0.53) | CDK2PRKCZCDK4CCNA2CCND1 | |
| SCHEMBL18576289 | 0.84 | PDGFRB (0.46) | CDK2CDK4CCNA2CCND1KDR | |
| SCHEMBL18562032 | 0.75 | CDK2 (0.56) | CDK2PRKCZCDK4CCNA2CCND1 | |
| SCHEMBL17251712 | 0.73 | PARP1 (0.59) | FYNBRD4 | |
| SCHEMBL17251710 | 0.72 | PDGFRB (0.56) | CDK2CDK4CCNA2CCND1KDR | |
| SCHEMBL8818585 | 0.70 | PARP1 (0.62) | BRD4 | |
| SCHEMBL18562035 | 0.70 | BRD4 (0.49) | KDRAURKAFLT4FLT3BRD4 | |
| SCHEMBL5952843 | 0.70 | CDK2 (0.64) | CDK2PRKCZCDK4CCNA2CCND1 | |
| SCHEMBL5952685 | 0.69 | FGFR1 (0.63) | CDK2CDK4CCNA2CCND1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057930-A1 | COMPOUNDS FOR TREATMENT OF CANCER | TP53, TUBB1, TUBB6 | CDK2 298/4885PRKCZ 2364/4885CDK4 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.